News topic
Comparison News & Updates
Head-to-head peptide comparisons covering mechanism, evidence, cost, and practical differences.
31 articles in this topic
Semaglutide vs Tirzepatide: Mechanisms, Efficacy, and Clinical Differences
Two of the most effective weight loss medications available are semaglutide and tirzepatide. Here we compare their mechanisms of action, clinical trial results, and practical differences for patients.
BPC-157 vs TB-500: Recovery Peptides Compared
BPC-157 and TB-500 are two peptides heavily promoted for tissue repair and recovery. We review what animal research actually shows and how they differ mechanistically.
Ipamorelin vs CJC-1295: GH Secretagogues Compared
Ipamorelin and CJC-1295 are two distinct GH secretagogues often used together. We explain how they work, why they are stacked, and what evidence exists.
MK-677 vs Sermorelin: Oral Non-Peptide vs Injectable GHRH
MK-677 and sermorelin both boost growth hormone but work differently and have different routes of administration. We compare mechanisms, evidence, and practical trade-offs.
Selank vs Semax: Russian Nootropic Peptides Compared
Selank and semax are two Russian-developed nootropic peptides claimed to enhance cognition and mood. We explain how they differ and what evidence exists.
Ozempic vs Mounjaro: GLP-1 vs GLP-1/GIP Dual Agonist Comparison
Ozempic (semaglutide) and Mounjaro (tirzepatide) are the two most popular GLP-1 receptor agonists for weight loss. Mounjaro adds GIP receptor agonism for potentially superior efficacy, but costs more. Here's a detailed breakdown.
MK-677 vs Ipamorelin: Oral Secretagogue vs Injectable Peptide
MK-677 (oral growth hormone secretagogue) and Ipamorelin (injectable peptide GH releaser) both stimulate growth hormone, but differ fundamentally in mechanism, potency, and side effects. Here's the detailed comparison.
MK-677 vs CJC-1295: Ghrelin Mimetic vs GHRH Analog
MK-677 and CJC-1295 both stimulate growth hormone but target different pathways. MK-677 mimics ghrelin; CJC-1295 is a GHRH analog. Here's how they compare.
Sermorelin vs Ipamorelin: GHRH vs GHRP Growth Hormone Release
Sermorelin is FDA-approved for growth hormone deficiency; Ipamorelin is investigational. Both stimulate GH but through different mechanisms. Here's the comprehensive comparison.
BPC-157 vs GHK-Cu: Healing Peptide Comparison for Tissue Repair
Both BPC-157 and GHK-Cu are popular healing peptides. BPC-157 targets broad tissue repair; GHK-Cu has topical availability and collagen-promoting effects. Here's the detailed comparison.
Semaglutide vs Retatrutide: Single vs Triple Agonist Weight Loss
Retatrutide is a next-generation triple agonist (GLP-1/GIP/GCG) showing even greater weight loss than tirzepatide. Semaglutide is approved and widely available. Here's how they compare.
PT-141 vs Melanotan II: Melanocortin Agonists and Sexual Function
PT-141 is FDA-approved for sexual dysfunction; Melanotan II is experimental and carries significant safety concerns. Here's the comprehensive comparison of these melanocortin agonists.
Sermorelin vs CJC-1295: Short-Acting vs Long-Acting GHRH Analogs
Both sermorelin and CJC-1295 are GHRH analogs that stimulate growth hormone. The key difference is half-life: sermorelin requires frequent dosing; CJC-1295 (especially with DAC) requires fewer injections. Here's the detailed comparison.
Tesamorelin vs Sermorelin: GHRH Analogs Compared
Both are GHRH analogs that stimulate growth hormone release, but tesamorelin's trans-3-hexenoic acid modification gives it superior half-life and receptor binding.
AOD-9604 vs Semaglutide: Fat Loss Peptides Compared
AOD-9604 and semaglutide are often compared for fat loss, but their evidence profiles differ dramatically: semaglutide has extensive Phase 3 data and FDA approval; AOD-9604 failed Phase 2b trials.
Tirzepatide vs Retatrutide: Dual vs Triple GIP/GLP-1/Glucagon Agonists
Tirzepatide is FDA-approved for weight loss with robust efficacy (20-22% weight loss). Retatrutide adds glucagon receptor agonism for potentially superior outcomes, but remains in Phase 3 trials.
BPC-157 vs Sermorelin: Tissue Repair vs GH Stimulation
BPC-157 and sermorelin are frequently discussed together but target entirely different pathways: BPC-157 promotes tissue repair; sermorelin stimulates growth hormone. Understanding these differences is essential.
Ipamorelin vs MK-677: GHRP vs Ghrelin Agonist
Ipamorelin (GHRP) and MK-677 (ghrelin agonist) both stimulate GH but through different receptors and mechanisms. This is the reverse of our MK-677 vs Ipamorelin article with distinct framing.
TB-500 vs GHK-Cu: Thymosin vs Copper Peptide Healing
TB-500 and GHK-Cu are both healing peptides but target different pathways: TB-500 regulates actin; GHK-Cu activates copper-dependent gene expression and collagen synthesis.
CJC-1295/Ipamorelin Stack vs Sermorelin: Combo vs Single Agent
The CJC-1295/ipamorelin stack combines GHRH + GHRP for theoretical synergy. Sermorelin is a single GHRH agonist. Do combinations outperform single agents?
Thymosin Alpha-1 vs BPC-157: Immune Modulation vs Tissue Repair
Thymosin alpha-1 modulates immunity and is approved in 35+ countries. BPC-157 promotes tissue repair but lacks human efficacy trials. Very different peptides for different purposes.
Epithalon vs GHK-Cu: Telomerase Activation vs Copper-Dependent Repair
Epithalon targets telomerase and cellular aging; GHK-Cu activates copper-dependent enzymes for collagen synthesis. Both claim anti-aging benefits, but evidence profiles differ significantly.
Melanotan II vs PT-141: Melanocortin Peptides Compared
Side-by-side comparison of Melanotan II and PT-141, two melanocortin receptor agonists used for tanning and sexual function enhancement.
MK-677 vs Sermorelin: Oral vs Injectable GH Booster
Side-by-side comparison of MK-677 and sermorelin, two growth hormone secretagogues with different administration routes and profiles.
NAD+ vs Epithalon: Anti-Aging Approaches Compared
Two distinct anti-aging approaches: NAD+ (cellular energy) and epithalon (telomere-focused). Evidence, mechanisms, and practical comparison.
MOTS-c vs AOD-9604: Metabolic Peptides Compared
MOTS-c and AOD-9604 are both metabolic peptides, but target different pathways: mitochondrial function vs. lipolysis and metabolic rate.
Semaglutide vs AOD-9604: Weight Loss Evidence Gap
Semaglutide has robust evidence for weight loss; AOD-9604 has minimal evidence. Direct comparison of proven vs. experimental weight loss peptides.
BPC-157 vs Thymosin Alpha-1: Repair vs Immunity
BPC-157 focuses on tissue repair and healing; thymosin alpha-1 targets immune restoration. Two distinct therapeutic peptides with different applications.
Retatrutide vs AOD-9604: Next-Gen vs Legacy Weight Loss
Retatrutide is a newer triple GLP-1/GIP/GCG agonist showing superior weight loss vs. legacy compounds like AOD-9604.
Selank vs NAD+: Cognitive Enhancement Approaches
Selank and NAD+ both support cognition but via different pathways: anxiolytic vs. mitochondrial enhancement.
Survodutide vs Tirzepatide vs Retatrutide: Next-Gen Weight Loss Drugs Compared
Three multi-agonist peptides are competing to define the next generation of obesity treatment. We compare their mechanisms, clinical data, and where each drug fits.